Shares of Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) traded up 18.7% on Thursday . The company traded as high as C$2.16 and last traded at C$1.97. 198,919 shares changed hands during trading, an increase of 89% from the average session volume of 105,118 shares. The stock had previously closed at C$1.66.
Medicenna Therapeutics Trading Up 16.3 %
The stock has a market cap of C$147.51 million, a price-to-earnings ratio of -4.37 and a beta of 1.21. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.51 and a quick ratio of 4.65. The company’s fifty day moving average price is C$2.03 and its 200-day moving average price is C$2.11.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.
See Also
- Five stocks we like better than Medicenna Therapeutics
- The Most Important Warren Buffett Stock for Investors: His Own
- NVIDIA’s Blackwell Chips Set for Arizona Manufacturing by TSMC
- The How And Why of Investing in Oil Stocks
- Okta: Bullish Signals Suggest a Market Reversal Is Underway
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- BlackRock Makes Waves With $12B Private Credit Acquisition
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
